Last week, President Trump declared the opioid epidemic a national public health emergency. The declaration allows federal agencies “to use every appropriate emergency authority to fight the opioid crisis.” The…
The House Energy & Commerce Subcommittee on Oversight and Investigations held its second hearing on the 340B drug program last Wednesday. Five covered entities – including RWC-340B member AIDS Resource…
This week, 57 Senators signed a bipartisan letter to CMS urging the agency to reconsider its proposal to reduce Medicare Part B reimbursement for 340B drugs. The proposed rule would…
The House Energy and Commerce (E&C) Committee will hold a hearing focused on the 340B program before the Oversight and Investigations Subcommittee on Wednesday, October 11 at 10 a.m. The hearing…
Mylan will refund 340B covered entities a total of $19.3 million for overcharges on the EpiPen as part of its recent settlement agreement with the Department of Justice resolving claims…
The Government Accountability Office (GAO) submitted a report on 340B program oversight as part of its testimony during the House Energy and Commerce’s Subcommittee on Oversight and Investigations hearing on…
We received a copy of what we believe to be the Trump Administration’s draft executive order on drug prices that would direct HRSA to scale back the 340B Program. According…
The Senate Health, Education, Labor and Pensions (HELP) Committee will hold a hearing “in the near future” on drug spending. A bipartisan group of senators who serve on the HELP…
A notice from Johnson & Johnson (J&J) was posted on the HRSA website stating that J&J will be issuing refunds to covered entities for overcharges on certain drugs sold between…
The U.S. Government and Accountability Office (GAO) is examining 340B contract pharmacy arrangements, although we do not yet know the purpose of the GAO’s review. The GAO is the investigative…